# Motixafortide for MRD Sensitization in AML

> **NCT07392970** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 10 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Measurable Residual Disease

## Interventions

- **DRUG:** Motixafortide

## Key facts

- **NCT ID:** NCT07392970
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-31
- **Primary completion:** 2028-06-02
- **Final completion:** 2029-12-02
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07392970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07392970, "Motixafortide for MRD Sensitization in AML". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07392970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*